For decades, KRAS was the mutation oncologists feared most and treated least. Dubbed "undruggable" by researchers who spent careers trying and failing to block it, KRAS G12D sits at the molecular heart of some of the deadliest cancers known to medicine — including non–small-cell lung cancer and pancreatic ductal adenocarcinoma. Now, a first-in-class investigational drug called setidegrasib is doing something no therapy has managed before: it isn't merely blocking the mutant protein. It is destroying it entirely. And the early numbers are turning heads across the oncology world.
Cracking the Code on an "Undruggable" Target
The story of KRAS is, in many ways, the story of modern oncology's most humbling adversary. KRAS — short for Kirsten Rat Sarcoma viral proto-oncogene — encodes a protein that acts as a molecular switch, cycling between active and inactive states to regulate cell growth. When mutated, that switch gets stuck in the "on" position, driving uncontrolled proliferation. The G12D substitution variant, in which glycine is replaced by aspartate at codon 12, is particularly prevalent and particularly stubborn. It occurs in approximately 5% of patients with non–small-cell lung cancer and is the most common substitution variant found in pancreatic ductal adenocarcinoma 4. For years, the smooth surface of the KRAS protein offered no obvious pocket for a drug molecule to latch onto, earning it its infamous "undruggable" reputation.
Setidegrasib approaches the problem from an entirely different angle. Rather than inhibiting the protein's function, it leverages the cell's own disposal machinery — the ubiquitin-proteasome system — to tag and degrade the mutant KRAS G12D protein altogether 18. This mechanism, known as targeted protein degradation, represents a conceptual leap in precision oncology. Where inhibitors leave the protein present but weakened, degraders eliminate it entirely, potentially offering deeper and more durable suppression of the oncogenic signal.
The drug was developed under the clinical trial identifier NCT05382559 and has been advancing through Phase 1 evaluation 11. Data from that study were presented at the 2026 European Lung Cancer Congress and simultaneously published in the New England Journal of Medicine, an unusual dual-release that underscored the scientific community's appetite for these results 9. The findings confirmed what early preclinical work had suggested: that a KRAS G12D degrader could produce meaningful, measurable responses in patients who had already exhausted multiple lines of therapy. For a field accustomed to incremental gains, the data felt like something closer to a breakthrough.
---
""For a field accustomed to incremental gains, setidegrasib's early data felt like something closer to a breakthrough.""
Numbers That Matter — What the Trial Actually Found
Clinical trials live and die by their numbers, and setidegrasib's Phase 1 data delivered figures that stood out even in a competitive landscape of targeted therapies. In pretreated patients with advanced non–small-cell lung cancer harboring the KRAS G12D mutation, setidegrasib produced an objective response rate of 36% — a striking result for a population that had already progressed on prior lines of treatment 2. Median progression-free survival reached 8.3 months 2, a duration that compares favorably with historical benchmarks for second- or third-line NSCLC therapy. In 45 evaluable patients with NSCLC, the overall response rate was confirmed at 35.8% 9, offering statistical consistency across the reporting.
The pancreatic cancer cohort told a similarly encouraging story, albeit with the sobering context that pancreatic ductal adenocarcinoma remains one of the most treatment-resistant malignancies in existence. Approximately 24% of patients with pancreatic cancer responded to setidegrasib 5 — a figure that, in the context of a disease where second-line response rates frequently hover in the single digits, carries genuine clinical weight. Memorial Sloan Kettering Cancer Center, one of the institutions involved in reporting these findings, noted that both settings represented areas where historically resistant therapies had failed 5, lending additional significance to even modest response rates.
The study enrolled twelve patients in one reported cohort, with a mean age of 57.66 years; seven had pancreatic cancer and five had lung cancer 3. Broader enrollment across the full Phase 1 dataset extended these findings to a larger evaluable population. Importantly, the drug demonstrated a low incidence of treatment discontinuation due to adverse events 1, a metric that oncologists increasingly regard as a critical measure of real-world tolerability. High response rates mean little if patients cannot remain on therapy long enough to benefit. Setidegrasib, based on early data, appears to thread that needle with relative success.
---
""Where inhibitors leave the protein present but weakened, degraders eliminate it entirely — a conceptual leap that could redefine precision oncology.""
The Safety Profile — Tolerability in a Difficult Population
Efficacy grabs headlines, but tolerability determines whether a drug survives the journey from clinical trial to clinical practice. Patients with advanced NSCLC and pancreatic cancer are often heavily pretreated, their bodies bearing the cumulative toll of prior chemotherapy, immunotherapy, and targeted agents. In this context, a drug's safety profile is not a secondary consideration — it is foundational to its viability. Setidegrasib's early-phase data suggest a manageable safety profile that supports continued dosing in a vulnerable patient population.
According to data presented at the 2026 European Lung Cancer Congress and reported across multiple oncology news outlets, setidegrasib demonstrated clinical activity alongside a tolerability profile that permitted most patients to remain on treatment 9. The low rate of discontinuation due to adverse events 1 is particularly meaningful in a Phase 1 setting, where dose escalation and exploration of the safety boundary are primary objectives. The fact that patients were not being driven off therapy by toxicity speaks well of the drug's therapeutic index — the balance between its beneficial effects and its harmful ones.
Florida Cancer Specialists & Research Institute, one of the participating sites in the Phase 1 study, highlighted that setidegrasib targets and breaks down KRAS G12D in a way that has historically been resistant to other therapies 8, and emphasized that the early-phase participation of community oncology practices broadens the generalizability of the safety findings beyond academic medical centers alone 13. This is a meaningful distinction. When a drug performs well only in the highly controlled environment of a major cancer center, its translation to broader practice can be uncertain. Community site participation in early-phase trials helps close that gap.
Biomarker analyses are also emerging as a critical component of the safety and efficacy picture. Phase 1 data indicate that biomarker-linked benefit may help identify which patients are most likely to respond 7, suggesting that a companion diagnostic strategy could further refine the drug's risk-benefit profile in future development phases. As precision oncology matures, the ability to match the right drug to the right patient — and to anticipate who might experience toxicity — becomes as important as the drug's mechanism itself.
---
""A 36% response rate in a previously treated population is not a footnote. It is the beginning of a new chapter.""
What Comes Next — The Road to Regulatory Consideration
The oncology pipeline is littered with promising Phase 1 results that failed to survive the rigors of larger, randomized trials. Setidegrasib's developers and the broader scientific community are acutely aware of that history. Yet the convergence of a novel mechanism, consistent efficacy signals across two tumor types, and a manageable safety profile has prompted serious discussion about accelerated development pathways and the drug's potential place in the standard-of-care landscape.
Astellas, the pharmaceutical company advancing setidegrasib, has signaled intent to move toward pivotal trial evaluation 19, a step that would represent a significant escalation of investment and a formal bid for regulatory review. The move from Phase 1 to a pivotal registration trial requires not only confidence in the drug's activity but also agreement with regulatory agencies on endpoints, patient selection criteria, and comparator arms — negotiations that will shape how broadly setidegrasib might ultimately be used. Given that KRAS G12D occurs in 5% of NSCLC cases and represents the most common KRAS variant in pancreatic cancer 4, the potential patient population, while molecularly defined, is clinically substantial.
The broader implications of setidegrasib's early success extend beyond the drug itself. Targeted protein degradation as a modality is still in its relative infancy, and a successful clinical validation in KRAS G12D — arguably the most high-profile target in solid tumor oncology — would accelerate investment and innovation across the entire degrader field 7. Researchers at institutions including Memorial Sloan Kettering have framed the results as supporting protein degradation as a new precision oncology paradigm 2, a characterization that, if borne out in larger trials, would mark a genuine inflection point in how oncologists think about treating RAS-driven cancers.
For patients with KRAS G12D-mutant lung or pancreatic cancer, the message emerging from this data is carefully optimistic. These are people who have frequently been told that their mutation is among the hardest to treat, that their options are limited, that the biology is working against them. Setidegrasib does not yet carry the weight of Phase 3 evidence or regulatory approval. But in the language of clinical data, a 36% response rate and 8.3 months of progression-free survival in a previously treated population 2 is not a footnote. It is the beginning of a new chapter.
---